JW Therapeutics: Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress

SHANGHAI, May 30, 2024 /PRNewswire/ -- JW (Cayman) Therapeutics Co. Ltd (the "Company" or "JW Therapeutics", together with its subsidiaries, the "Group"), an independent and innovative biotechnology

Related Keywords

China ,Hong Kong ,Shanghai ,Markj Gilbert ,A Bristol Myers Squibb ,Ltd The Company ,Prnewswire Jw Cayman Therapeutics Co ,China National Medical Products Administration ,National Significant New Drug Development Program ,Rheumatology Congress ,Clearing Limited Hkex ,European Alliance Of Associations ,Investigational New Drug ,Biologics License Application ,Chief Medical Officer ,Juno Therapeutics ,Bristol Myers Squibb ,Stock Code ,Hong Kong Exchanges ,Clearing Limited ,Ihr Portfolio ,